Publications – Drugs and health products
On this page
- Antimicrobial resistance
- Biologics, Radiopharmaceuticals and Genetic Therapies
- Blood products
- Cannabis
- Health Products and Medical Devices
- Self-care products
- Shortages and discontinuations
- Veterinary drugs
Antimicrobial resistance
- Pan-Canadian Action Plan on Antimicrobial Resistance
- Best Brains Exchange summary report on the antimicrobial business model
- Preserving Antibiotics Now and Into the Future: Chief Public Health Officer of Canada's Spotlight Report 2019
- Evidence synthesis summary: social and cultural drivers of antimicrobial use
- Evidence synthesis summary: interventions to address antimicrobial use
- Antimicrobial Resistance and Use in Canada: A Federal Framework for Action
- CIPARS: Working with others (Infographic)
- CIPARS 2020 highlights (Infographic)
- Federal Action Plan on Antimicrobial Resistance and Use in Canada: Building on the Federal Framework for Action
- Good Label and Package Practices Guide for Prescription Drugs [2016-06-30]
- Health Canada New Drug Authorizations: 2016 Highlights
- Health Canada New Drug Authorizations: 2015 Highlights
- Help reduce the spread of antimicrobial resistance (Poster)
- Human Antimicrobial Use Report - 2014
- National Surveillance of Antimicrobial Susceptibilities of Neisseria gonorrhoeae - Annual Summary 2013
- National Surveillance of Antimicrobial Susceptibilities of Neisseria gonorrhoeae - Annual Summary 2014
- National Surveillance of Antimicrobial Susceptibilities of Neisseria gonorrhoeae – 2015
- National Surveillance of Antimicrobial Susceptibilities of Neisseria gonorrhoeae - Annual Summary 2016
- National Surveillance of Antimicrobial Susceptibilities of Neisseria gonorrhoeae - Annual Summary 2017
- National surveillance of antimicrobial susceptibilities of Neisseria gonorrhoeae annual summary 2018
- National surveillance of antimicrobial susceptibilities of Neisseria gonorrhoeae annual summary 2019
- Progress Report on the 2015 Federal Action Plan on Antimicrobial Resistance and Use
- Summary Report on Antimicrobial Resistant Organisms Surveillance Data from January 1, 2011 to December 31, 2015
- Surveillance Bulletin: Reductions in Antimicrobial Use and Resistance: Preliminary Evidence of the Effect of the Canadian Chicken Industry's Elimination of Use of Antimicrobials of Very High Importance to Human Medicine
- Surveillance to action: the third-generation cephalosporin-resistant Salmonella from poultry story
- Research summary: antimicrobial use in lactating sows, suckling and nursery pigs
- Tackling Antimicrobial Resistance and Antimicrobial Use: A Pan-Canadian Framework for Action
- Working together to promote the responsible use of antimicrobials in animals (Infographic)
Canadian Antimicrobial Resistance Surveillance System
- Canadian Antimicrobial Resistance Surveillance System Executive summary 2024
- Canadian Antimicrobial Resistance Surveillance System Executive summary 2023
- Canadian Antimicrobial Resistance Surveillance System (CARSS) Report, 2022
- Infographic: Canadian Antimicrobial Resistance Surveillance System Report 2021
- Canadian Antimicrobial Resistance Surveillance System Report 2021
- Canadian Antimicrobial Resistance Surveillance System - Update 2020
- Canadian Antimicrobial Resistance Surveillance System 2018 Update - Executive Summary
- Canadian Antimicrobial Resistance Surveillance System Report 2017
- Canadian Antimicrobial Resistance Surveillance System Report 2016
Biologics, Radiopharmaceuticals and Genetic Therapies
Naming of Biologic Drugs
Blood products
- Transfusion Transmitted Injuries Surveillance System, 2022: Infographic
- Transfusion Transmitted Injuries Surveillance System Summary Report, 2016 to 2020
- Transfusion Transmitted Injuries Surveillance System (TTISS), 2018-2019 (Infographic)
- Transfusion Transmitted Injuries Surveillance System 2011 - 2015 Summary Report
- Transfusion Error Surveillance System (TESS), 2022 (Infographic)
- Transfusion Error Surveillance System (TESS) - 2012-2013 Report
Cannabis
- Brochure: How to help prevent cannabis poisoning in children
- Data on cannabis adverse reactions: 2022 annual report
- Data on cannabis adverse reactions: 2021 annual report
- Data on cannabis adverse reactions: 2020 annual report
- Data on cannabis adverse reactions: 2018-2019 annual report
- Reduce Your Risk: Choose Legal Cannabis (infographic)
- Canadian cannabis survey 2020 - Summary
- Canadian Cannabis Survey 2019 - Summary
- Canadian Cannabis Survey 2018 - Summary
- Canadian cannabis survey 2017 - Summary
- Summary report: Consultation on potential market for health products containing cannabis that would not require practitioner oversight
- Cannabis adverse reaction reporting guide
- Guide on composition requirements for cannabis products
- Notice of new cannabis product guide: Requirements under section 244 of the Cannabis Regulations
- Cannabis voluntary recall guide
- Mandatory cannabis testing for pesticide active ingredients - Requirements
- Mandatory cannabis testing for pesticide active ingredients - List and limits
- Is cannabis addictive?
- Is cannabis safe to use? Facts for youth aged 13–17 years
- Is cannabis safe to use? Facts for young adults aged 18–25 years
- Does cannabis use increase the risk of developing psychosis or schizophrenia?
- Is cannabis safe during preconception, pregnancy and breastfeeding?
- Cannabis and your health: 10 ways to reduce risks when using
- Cannabis licensing application web pages
- Guidance for health products containing cannabis or for use with cannabis
- Industrial hemp licensing application guide
- Cannabis Fees Order Guide
- Types of cannabis and industrial hemp licences
Cannabis for medical purposes
- Annual Compliance and Enforcement Report 2015-2016
- Understanding the New Access to Cannabis for Medical Purposes Regulations
Health Products and Medical Devices
- Guidance on distinction between advertising and other activities for health products [2023-07-31]
- Guidance on releasing information from adverse reaction and medical device incident reports to the public [2022-08-31]
- Health product highlights 2021: Helping you maintain and improve your health [2022-08-03]
- Guidance to market authorization holders on issuing health product risk communications [2022-05-25]
- Event Summary: Health Canada's stakeholder update on health products [2022-04-11]
- Mid-year update: Health products approved in 2021
- Drug and medical device highlights 2020: Helping you maintain and improve your health [2021-07-27]
- Medical Devices Action Plan: Progress report [2021-05-28]
- Event Summary: Health Canada's 2020 virtual stakeholder meeting on health products [2021-03-03]
- Drug and medical device highlights 2019: Helping you maintain and improve your health [2020-05-28]
- Drug and medical device highlights 2018: Helping you maintain and improve your health [2019-06-27]
- Suspect a serious adverse drug reaction or medical device incident (poster)
- Good Label and Package Practices Guide for Prescription Drugs [2019-06-21]
- Final Report: Fees for Drugs and Medical Devices [2019-05-15]
- Performance Standards for the Fees in Respect of Drugs and Medical Devices Order [2019-05-15]
- Format and content for post-market drug benefit-risk assessment in Canada - Guidance document
- Notifying Health Canada of Foreign Actions - Guidance Document for Industry
- Good Label and Package Practices Guide for Non-prescription Drugs and Natural Health Products
- Reporting Adverse Reactions to Marketed Health Products - Guidance Document for Industry
- Preparing and Submitting Summary Reports for Marketed Drugs and Natural Health Products - Guidance Document for Industry
- Submission of targeted risk management plans and follow-up commitments for prescription opioid-containing products - Guidance for industry
- What we heard: A summary of scanning and consultations on what's next for health product regulation
- Guidance document on Public Release of Clinical Information
- Stop illegal marketing of drugs and devices infographic
- Consultation Summary: Health Products Stakeholder Engagement Session June 27, 2018
- Annual trends for the adverse reaction case reports of health products and medical device problem incidents to Health Canada (2008-2017)
- Drug and health product compliance monitoring reports
Self-care products
Shortages and discontinuations
- Guide to reporting drug shortages and discontinuations
- Guide to distributing drugs intended for the Canadian market for consumption or use outside Canada
- Guide on the requirements for providing information related to drug shortages
- Guide to the exceptional importation and sale of drugs in response to drug shortages
Veterinary drugs
- 2023 Veterinary Antimicrobial Sales Highlights Report
- 2022 Veterinary Antimicrobial Sales Highlights Report
- 2021 Veterinary Antimicrobial Sales Highlights Report
- 2020 Veterinary Antimicrobial Sales Highlights Report
- 2019 Veterinary Antimicrobial Sales Highlights Report
- What We Heard - Responses to the Public Consultation on a proposed Teat Antiseptic Product Monograph
- Antiseptic Teat Solutions Monograph
Page details
- Date modified: